Novocure Ltd. (NVCR): Price and Financial Metrics


Novocure Ltd. (NVCR): $76.83

-3.21 (-4.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVCR POWR Grades

  • Stability is the dimension where NVCR ranks best; there it ranks ahead of 67.96% of US stocks.
  • The strongest trend for NVCR is in Growth, which has been heading down over the past 178 days.
  • NVCR ranks lowest in Momentum; there it ranks in the 10th percentile.

NVCR Stock Summary

  • The price/operating cash flow metric for NOVOCURE LTD is higher than 97.96% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 15.77, NOVOCURE LTD has a higher such ratio than 92.9% of stocks in our set.
  • Over the past twelve months, NVCR has reported earnings growth of 690.94%, putting it ahead of 97.36% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NOVOCURE LTD are ALTR, DUOL, ROKU, FROG, and LGND.
  • To check out NOVOCURE LTD's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.

NVCR Valuation Summary

  • NVCR's EV/EBIT ratio is -124.9; this is 1535.63% lower than that of the median Healthcare stock.
  • NVCR's price/sales ratio has moved down 60.3 over the prior 87 months.

Below are key valuation metrics over time for NVCR.

Stock Date P/S P/B P/E EV/EBIT
NVCR 2022-12-02 15.5 18.9 -102.8 -124.9
NVCR 2022-12-01 15.8 19.2 -104.8 -127.1
NVCR 2022-11-30 14.9 18.1 -98.7 -120.1
NVCR 2022-11-29 14.4 17.6 -95.9 -116.9
NVCR 2022-11-28 13.6 16.5 -90.0 -109.9
NVCR 2022-11-25 14.5 17.7 -96.4 -117.3

NVCR Growth Metrics

    Its 5 year revenue growth rate is now at 358.25%.
  • Its 4 year price growth rate is now at 826.76%.
  • Its 2 year cash and equivalents growth rate is now at 4.88%.
Over the past 18 months, NVCR's revenue has gone up $15,391,000.

The table below shows NVCR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 542.624 48.899 -81.689
2022-06-30 545.232 50.879 -68.237
2022-03-31 539.365 64.665 -36.54
2021-12-31 535.031 82.756 -58.351
2021-09-30 545.771 121.833 -26.976
2021-06-30 544.825 128.402 -4.568

NVCR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVCR has a Quality Grade of B, ranking ahead of 83.73% of graded US stocks.
  • NVCR's asset turnover comes in at 0.503 -- ranking 92nd of 186 Medical Equipment stocks.
  • IDXG, HAE, and CTSO are the stocks whose asset turnover ratios are most correlated with NVCR.

The table below shows NVCR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.503 0.792 -0.008
2021-06-30 0.597 0.795 0.016
2021-03-31 0.685 0.794 0.047
2020-12-31 0.786 0.785 0.059
2020-09-30 0.926 0.771 0.057
2020-06-30 0.837 0.761 0.019

NVCR Price Target

For more insight on analysts targets of NVCR, see our NVCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $177.14 Average Broker Recommendation 2.06 (Hold)

NVCR Stock Price Chart Interactive Chart >

Price chart for NVCR

NVCR Price/Volume Stats

Current price $76.83 52-week high $94.00
Prev. close $80.04 52-week low $56.39
Day low $75.35 Volume 312,351
Day high $79.46 Avg. volume 596,109
50-day MA $75.47 Dividend yield N/A
200-day MA $76.32 Market Cap 8.06B

Novocure Ltd. (NVCR) Company Bio


NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.


NVCR Latest News Stream


Event/Time News Detail
Loading, please wait...

NVCR Latest Social Stream


Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

Is NovoCure Limited (NVCR) a opportunity to investors?

The share price of NovoCure Limited (NASDAQ:NVCR) rose to $81.54 per share on Thursday from $76.84. While NovoCure Limited has overperformed by 6.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVCR fell by -10.46%, with highs and lows ranging from $95.58 to $56.39, whereas the […]

US Post News | December 2, 2022

NovoCure''s Stock Could Soar In 2023 (NASDAQ:NVCR)

NovoCure''s Q3 2022 results were mediocre but that''s not what this stock is about. Read more to see why I rate NVCR stock a buy.

Seeking Alpha | November 30, 2022

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma.

Business Wire | November 29, 2022

NovoCure takes off on Wells Fargo''s optimism for LUNAR program

NovoCure (NVCR) was upgraded by Wells Fargo on Tuesday on hopes of a positive outcome from the company''s LUNAR trial, which is studying the efficacy of tumor treating fields…

Seeking Alpha | November 29, 2022

Why Novocure Stock Is Jumping Today

Novocure''s innovative cancer therapy picked up a big win in Canada.

The Motley Fool | November 29, 2022

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo 8.87%
3-mo -3.04%
6-mo -0.54%
1-year -6.37%
3-year -7.73%
5-year 284.15%
YTD 2.33%
2021 -56.61%
2020 105.34%
2019 151.70%
2018 65.74%
2017 157.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8134 seconds.